drugset / Trial / NCT05918276
Clinical Study of Orelabrutinib Combined With BG Regimen First-line Treatment of CLL/SLL
NaSingle-groupOpen-labelTreatment
Summary
This study aims to investigate the treatment of navie CLL/SLL with orelabrutinib, bendamustine and obinutuzumab . The primary endpoint is the rate of CR and uMRD, and the second endpoints are survival time (OS and PFS) and toxicities.
Timeline
- Start
- 2023-07-15
- Primary completion
- 2024-12-30
- Completion
- 2026-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bendamustin | Unknown | 70 mg/m2 | Intravenous |
| Subject | Obintuzumab | Unknown | 1000 mg/m2 | Intravenous |
| Subject | Orelabrutinib | Small molecule | 200 mg | Oral |